Hepatitis C leads today’s briefing, with practical lessons on post-operative complication review, thalassaemia clues, and why approval headlines still need closer reading.
Do not let a reassuring first answer outrun the history, the timeline, or the confirmatory test.
Today’s strongest listens cover hepatitis C case finding, post-operative complication review, thalassaemia behind microcytic anaemia, and the evidence behind new drug approvals. Start with the hepatitis C episode: it takes a common problem—abnormal liver blood tests, incomplete exposure histories, and hard-to-read serology—and turns it into a workable plan for testing, RNA confirmation, referral, and repeat testing when risk continues.
The rest of the list builds the same habit of not stopping too early. The M&M episode shows how to make post-operative haemorrhage and anastomotic leak visible without blame or hindsight. The thalassaemia episode sharpens recognition of jaundice, splenomegaly, and poor growth when microcytic anaemia is not the whole story. The FDA episode is shorter but useful when approval headlines sound stronger than the evidence behind them. The shared takeaway is simple: before you reassure yourself, make sure the history, timeline, or confirmatory test actually supports it.
An abnormal liver panel or a remote exposure history should still open the hepatitis C pathway. This episode earns first place because it makes testing, antibody and RNA interpretation, referral, and repeat testing after ongoing risk feel usable in day-to-day primary care.
The pitfall is turning an M&M case into a discharge summary and burying the complication. Worth opening for its practical rules on one-sentence headlines, clean timelines, decision points, and no-blame analysis of post-operative haemorrhage or anastomotic leak.
The clue is microcytic anaemia that comes with jaundice, splenomegaly, or poor growth rather than sitting alone. This is a strong listen for anyone who wants a quick route from suspicion to haemoglobin electrophoresis, ferritin monitoring, and severity-based thinking.
Do not treat a new approval headline as a complete account of the evidence. This short critical appraisal episode clarifies what a one-trial FDA default means, what it does not mean, and why that distinction matters when new therapies or devices are discussed.
When abnormal liver tests, chronic microcytic anaemia, or post-operative deterioration do not quite fit the first explanation, reopen the case rather than rounding it off. The common pitfall is accepting the early antibody result, the familiar anaemia label, or the long narrative that hides the key decision point. Go back for the exposure history, the RNA result or haemoglobin electrophoresis, or the explicit escalation moment that changes what happens next.
When should hepatitis C stay on the list even if the patient feels well?
Risk factors and unexplained abnormal liver blood tests are enough to test. The episode specifically flags current or previous intravenous drug use, prison history, homelessness, sex work, men who have sex with men, migration from higher-prevalence regions, and transfusion before 1996.
What makes an M&M presentation useful rather than defensive?
Lead with a one-sentence complication headline, then show chronology, objective data, and the main decision points. Keep the account factual and separate individual decisions from system constraints instead of letting hindsight drive the discussion.
Which findings in microcytic anaemia should make me think about thalassaemia?
Jaundice, splenomegaly, poor growth, or bony facial changes make thalassaemia more likely. That is the point to move beyond the full blood count towards haemoglobin electrophoresis and ferritin monitoring.
.svg)